Liver/Biliary Disorders News

PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, provides an overview of her postgraduate course presentation at the ACG Annual Scientific Meeting.

PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, discusses recent efforts to advance elimination of hepatitis C virus.

The FDA issued a complete response letter to Intercept Pharmaceuticals indicating it cannot grant full approval to the company’s supplemental new drug application for Ocaliva as a treatment for primary biliary cholangitis.

As you read these words, you may be learning for the first time about hepatitis delta virus — a lesser-known type of hepatitis that is potentially life-threatening.

PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, speaks with Healio about the underutilization of palliative care for patients with end-stage liver disease.

PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, discusses data from the ongoing MAESTRO-NASH trial, which were presented at the ACG Annual Scientific Meeting.

PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, highlights a presentation evaluating the use of sodium-glucose cotransporter 2 inhibitors in patients with cirrhosis.

Recent advancements have been made in the treatment of primary biliary cholangitis, particularly for patients who do not respond adequately to first-line treatment.

PHILADELPHIA — Paul Kwo, MD, professor of medicine at Stanford University, speaks with Healio about presentations investigating the undertreatment of hepatitis B.

PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine at Stanford University, discusses a plenary session about the “emerging role” of mycophenolate mofetil for the treatment of autoimmune hepatitis.